List of Excipients in Branded Drug EDARAVONE

Generic Drugs Containing EDARAVONE

Company	Ingredient	NDC	Excipient
Sandoz Inc	edaravone	0781-3527	CYSTEINE HYDROCHLORIDE
Sandoz Inc	edaravone	0781-3527	PHOSPHORIC ACID
Sandoz Inc	edaravone	0781-3527	SODIUM BISULFITE

What are the Most Frequently-Used Excipients in EDARAVONE?

# Of NDCs	Excipient
5	CYSTEINE HYDROCHLORIDE
5	PHOSPHORIC ACID
5	SODIUM BISULFITE

Exipient Strategy and Commercial Opportunities for Edaravone

Last updated: February 26, 2026

What is Edaravone and its current market use?

Edaravone is a free radical scavenger indicated primarily for the treatment of acute ischemic stroke and amyotrophic lateral sclerosis (ALS). It was approved in Japan in 2001 and later gained approvals in the United States (2017) under the brand Radicava. The drug's mechanism involves reducing oxidative stress, thereby limiting neuronal damage.

What are the key excipient considerations for Edaravone formulation?

Common excipients in Edaravone formulations

Edaravone is administered via intravenous infusion, requiring specific excipient strategies to ensure stability and bioavailability:

• Solvents: Dimethyl sulfoxide (DMSO) was initially used but is now avoided due to toxicity concerns. Instead, saline solutions with stabilizers are common.
• Stabilizers and antioxidants: Mannitol, sodium hydroxide, and phosphate buffers maintain pH and stability.
• Surfactants: Polysorbate 80 has been considered to improve solubility.
• Preservatives: Not typically used in injectable formulations to reduce adverse effects.

Challenges and strategies

• Chemical stability: Edaravone is prone to oxidation; excipients like antioxidants are necessary.
• Solubility: Poor water solubility of Edaravone necessitates surfactants and appropriate pH buffers.
• Shelf life: Stabilizing agents extend product shelf life, which influences manufacturing and storage.

What are the commercial opportunities tied to excipient innovation?

Opportunities for novel excipient development

• Enhanced stability formulations: Developing excipients that improve oxidative stability could extend shelf life and reduce cold chain dependency.
• Prolonged-release formulations: Excipient systems enabling controlled release could reduce dosing frequency, expanding market segments.
• Alternative delivery methods: Liposomal or nanoparticle carriers with tailored excipients may facilitate oral or inhalation forms, broadening patient access.

Market dynamics and growth potential

• ALS drug market: The global ALS market is expected to reach USD 1.25 billion by 2027, driven by Edaravone's approval and off-label uses [2].
• Stroke treatment: As stroke remains a leading cause of death worldwide, demand for neuroprotective drugs like Edaravone sustains growth.
• Generic and biosimilar opportunities: Patent expirations open markets for formulations with alternative excipient systems, reducing costs.

Regulatory implications

• Modifications in excipient composition require regulatory review but can provide differentiation.
• Emphasizing excipient safety profiles aligns with increasing demands for excipient transparency and quality.

What are the key considerations for formulation development and commercialization?

Aspect	Details
Stability	Use antioxidants, buffer systems, or alternative excipients to prevent oxidation
Bioavailability	Optimize solubilization with surfactants or lipid-based excipients
Administration	Explore formulations amenable to alternative delivery routes to expand market reach
Regulatory	Ensure excipient safety complies with ICH Q3A/B standards and regional requirements

What are potential risks and challenges?

• Excipient toxicity: Introduction of new excipients could trigger safety issues or regulatory hurdles.
• Manufacturing complexity: Novel formulations may require new process development.
• Cost implications: Advanced excipient systems and delivery methods can increase production costs.

Key takeaways

• Edaravone's formulation hinges on excipient strategies that improve stability and bioavailability.
• Innovation in excipient design can enable extended shelf life, alternative delivery routes, and new patent opportunities.
• The expanding ALS and stroke markets present commercial opportunities for formulations with optimized excipient systems.
• Regulatory compliance and safety profiles are crucial in excipient selection.
• Competitive advantage arises from formulations that balance efficacy, safety, and manufacturing efficiency.

FAQs

1. Can excipient modifications extend Edaravone's shelf life?
   Yes; antioxidants and stabilizers can prevent oxidation, prolonging product stability.

2. Are there oral formulations of Edaravone?
   Presence of oral formulations is limited; research is ongoing into liposomal and nanoparticle carriers.

3. What excipients are best suited for improving Edaravone solubility?
   Surfactants like polysorbate 80 and lipid-based excipients can improve solubility.

4. How do excipient choices impact regulatory approval?
   Regulatory bodies require safety data on excipients, and modifications must demonstrate bioequivalence or safety.

5. What market trends influence Edaravone excipient development?
   Growing neurodegenerative and stroke markets, alongside patent expiries, foster opportunities for innovative formulations.

---

References

1. [1] Edaravone. (2022). Pharmacology. Drugs.com.
2. [2] MarketWatch. (2022). Global ALS drug market analysis.
3. [3] ICH Q3A/B. (2006). Impurities in new drug substances and products. FDA.